Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw some unusual options trading on Tuesday. Stock traders purchased 22,702 put options on the company. This represents an increase of 797% compared to the typical daily volume of 2,532 put options.
Analyst Ratings Changes
Several brokerages have recently weighed in on CMPX. Wedbush reiterated an "outperform" rating and set a $8.00 price target on shares of Compass Therapeutics in a research report on Tuesday. Jefferies Financial Group increased their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, February 10th. D. Boral Capital reissued a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. Guggenheim reiterated a "buy" rating and set a $12.00 price target on shares of Compass Therapeutics in a research report on Wednesday. Finally, Piper Sandler assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective on the stock. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Compass Therapeutics has a consensus rating of "Buy" and a consensus target price of $13.38.
Read Our Latest Stock Analysis on Compass Therapeutics
Compass Therapeutics Stock Performance
NASDAQ:CMPX traded down $0.15 during mid-day trading on Friday, reaching $1.46. The stock had a trading volume of 1,726,053 shares, compared to its average volume of 814,985. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The firm has a 50 day moving average price of $2.76 and a two-hundred day moving average price of $2.10. The stock has a market capitalization of $201.89 million, a P/E ratio of -3.95 and a beta of 1.19.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of CMPX. Rhumbline Advisers boosted its holdings in Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company's stock valued at $187,000 after acquiring an additional 3,822 shares during the period. Invesco Ltd. lifted its position in Compass Therapeutics by 11.3% in the fourth quarter. Invesco Ltd. now owns 39,483 shares of the company's stock valued at $57,000 after purchasing an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Compass Therapeutics by 2.6% during the fourth quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company's stock valued at $345,000 after purchasing an additional 6,041 shares during the period. ProShare Advisors LLC grew its holdings in shares of Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after purchasing an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of Compass Therapeutics by 31.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock worth $69,000 after buying an additional 11,326 shares during the period. Hedge funds and other institutional investors own 68.43% of the company's stock.
About Compass Therapeutics
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Further Reading
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
